VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: VLAD who wrote (20391)	4/12/1999 8:07:00 PM
From: Edderd	Read Replies (1) of 23519

VLAD Got this today on UrologyFax. Vivus inc. has been issued broad protection for the commercialization of Alibra, its second generation transurethral treatment for male erectile dysfunction (ED). This is the first transurethral two-drug treatment to treat erectile dysfunction, uses alprostadil and prazosin to initiate and maintain smooth muscle relaxation. This product, currently in phase-lll trials, features a redisigned applicator and a single-strength formulation. Ineresting Eh. I hope its a gel you squeeze into the urethra. With a single dose it would really be easy to use. Note that a gel could be applied to a female _______. How about that idea. Ed

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next